Abstracts Archive - Page 1593 of 2425 - ACR Meeting Abstracts

Abstract Number: 2639 • 2016 ACR/ARHP Annual Meeting
Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Shintaro Hirata¹, Xingbin Wang², CC Hwang³, Ippei Miyagawa⁴, Satoshi Kubo¹, Kazuhisa Nakano⁵, Shingo Nakayamada⁵, Kazuyoshi Saito⁴, Nadine A. Defranoux² and Yoshiya Tanaka⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: The multi-biomarker disease activity (MBDA) (Vectra® DA) score has been reported to predict disease relapses in patients with rheumatoid arthritis (RA) in sustained remission…
Abstract Number: 2640 • 2016 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?
Masao Sato¹, Masao Takemura², Yasuko Yamamoto³ and Kuniaki Saito⁴, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Advanced Diagnostic System Research Laboratory, Fujita Health University, Toyoake, Japan, ³Disease Control and Prevention, Fujita Health University, Toyoake, Japan, ⁴Disease Control and Prevention, Fjita Health University, Aichi, Japan
Background/Purpose: GP88 (progranulin; PGRN) is a glycoprotein with a molecular weight of approximately 88,000 Da and is thought to play an important role in…
Abstract Number: 2641 • 2016 ACR/ARHP Annual Meeting
Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA
Sofia Ramiro¹, Alexandre Sepriano¹, Katerina Chatzidionysiou², Jackie L. Nam³, Josef Smolen⁴, Désirée van der Heijde⁵, Maxime Dougados⁶, Ronald van Vollenhoven⁷, Johannes WJ Bijlsma⁸, GR Burmester⁹, Marieke Scholte-Voshaar¹⁰ and RBM Landewé¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Paris Descartes University, Paris, France, ⁷Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité – University Medicine Berlin, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Medical Center, Amsterdam, Netherlands
Background/Purpose: As part of the update of the EULAR recommendations for the management of RA, we performed a systematic literature review to assess the safety…
Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…
Abstract Number: 2644 • 2016 ACR/ARHP Annual Meeting
Patient Survey Regarding Generic and Bio-Similar Drugs
Tsukasa Matsubara¹, Tamami Yoshitama¹, Kou Katayama¹, Shigehito Kiyokawa², Nobumasa Miyake², Motohiro Oribe², Akira Sagawa² and Keiko Funahashi³, ¹Japanese clinician biologics research group, Kobe, Hyogo, Japan, ²Japanese clinician biologics research group, Kobe, Japan, ³Clinical Research, Matsubara Mayflower Hospital, Kato, Japan
Background/Purpose: In Japan the market share for generic drugs is 50%, lower than that in Western nations. This is partially due to Japan’s insurance system,…
Abstract Number: 2645 • 2016 ACR/ARHP Annual Meeting
Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Salvador R. Garcia¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Department of Medicine. Section of Allergy Immunology and Rheumatology., Department of Medicine, Section of Allergy Immunology and Rheumatology, Baylor College of Medicine, Houston, Texas, USA., Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: The objective of this systematic review was to evaluate the clinical evidence on the efficacy of different drug regimens for the treatment of early…
Abstract Number: 2646 • 2016 ACR/ARHP Annual Meeting
Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Tzu-Chieh Lin¹, Mirhelen Mendes De Abreu², Sara K. Tedeschi¹, Kazuki Yoshida³ and Daniel H. Solomon², ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA
Background/Purpose: There is limited information for the rate of hepatitis B reactivation in inflammatory arthritis patients. We conducted a systematic review and meta-analysis, assessing hepatitis…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 2648 • 2016 ACR/ARHP Annual Meeting
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Bogdan Ion Gavrila¹, Claudia Ciofu², Victor Stoica³, Cornel Ursaciuc⁴, Dan Ciotaru⁴, Mihaela Surcel⁵, Adriana Munteanu⁴ and Eugenia Panaitescu⁶, ¹Internal Medicine and Rheumatology, Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ²Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ³Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁴INCD ,,Victor Babeș’’, Bucharest, Romania, Bucharest, Romania, ⁵INCD ,,Victor Babeș’’, Bucharest, Romania, bucharest, Romania, ⁶Carol Davila University of Medicine and Pharmacy ,Medical Informatics and Biostatistics, Bucharest, Romania
Background/Purpose: discovery of biomarkers that can identify pretreatment patients who will respond to biologic DMARDs therapy is one of the major interests in RA. We…
Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting
Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Fouad Fayad¹, Nelly Ziade², Georges Merheb^3,4, Said Attoui⁵, Alla Aiko⁶, Kamel Mroue⁵ and Abdel Fattah Masri⁷, ¹Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Holly Spirit University, Kaslik, Lebanon, ⁵Hammoud University Medical Center, Saida, Lebanon, ⁶Saint Georges Hospital, Beirut, Lebanon, ⁷American University of Beirut Medical Center, Beirut, Lebanon
Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Stefan Florentinus³, Su Chen³, Jessica L. Suboticki³ and Josef S. Smolen⁴, ¹Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…
Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Manon Redondin¹, B Combe², Cécile Gaujoux-Viala³, Jacques Morel⁴ and Cédric Lukas⁵, ¹CHU Lapeyronie, University of Montpellier, France, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
Abstract Number: 2653 • 2016 ACR/ARHP Annual Meeting
Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA
GR Burmester¹, MA Michaels², D Close³, A Godwood³, K Middleton³, P Miranda⁴, J Vencovský⁵, JM Kremer⁶, IB McInnes⁷, M Albulescu^³ and Michael Weinblatt⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶The Albany Medical College, Albany, NY, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Brigham and Women’s Hospital, Boston, MA
Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of…
Abstract Number: 2654 • 2016 ACR/ARHP Annual Meeting
Association Between Rheumatoid Factor Positivity and Effects of Treatment with a First Biologic Agent in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima³ and Naoki Ishiguro⁴, ¹orthopedic surgery, Sakashita Hospital, Nakatsugawa, Japan, ²Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: The presence of rheumatoid factor (RF) plays an important role in the diagnosis of rheumatoid arthritis (RA). However, whether RF positivity is related to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].